Modulation of the cationic amino acid transport system y+L by surface potential, ouabain and thrombin in human platelets: Effects of uremia

Nephron - Experimental Nephrology

Volumn 107, Issue 4, 2008, Pages

  Alves De Sá Siqueira, Mariana ^a   Martins, Marcela Anjos ^a   Rodrigues Pereira, Natália ^b   Bandeira Moss, Monique ^a   Santos, Sérgio F F ^a   Mann, Giovanni E ^c   Mendes Ribeiro, Antônio C ^a,b   Brunini, Tatiana M C ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

L Arginine transport; Modulation, nitric oxide; Platelets; Y+L system

Indexed keywords

4 CHLOROMERCURIBENZOIC ACID; AMINO ACID; AMINO ACID TRANSPORTER; ARGININE; LEUCINE; OUABAIN; SODIUM; THROMBIN;

ADULT; AMINO ACID TRANSPORT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; KINETICS; MALE; MALNUTRITION; MODULATION; PRIORITY JOURNAL; THROMBOCYTE; UREMIA;

ADULT; AMINO ACID TRANSPORT SYSTEM Y+L; ARGININE; BIOLOGICAL TRANSPORT; BLOOD PLATELETS; ENZYME INHIBITORS; GLUCOSE; HEMOSTATICS; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPOLYSACCHARIDES; MEMBRANE POTENTIALS; NITRIC OXIDE; OUABAIN; SODIUM; THROMBIN; TRITIUM; TUMOR NECROSIS FACTOR-ALPHA; UREMIA;

EID: 38049059344     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111040     Document Type: Article

References (38)

1. Morris SM Jr: Arginine metabolism: boundaries of our knowledge. J Nutr 2007;137:1602S-1609S.
2. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
3. Morris SM Jr: Enzymes of arginine metabolism. J Nutr 2004;134:2743S- 2747S.
4. Brunini TMC, da Silva CVD, Siqueira MAS, Moss MB, Santos SFF, Mendes-Ribeiro AC: Uraemia, atherothrombosis and malnutrition: the role of L-arginine-nitric oxide pathway. Cardiovasc Haematol Disord Drug Targets 2006;6:133-140.
5. Berkels R, Stockklauser K, Rosen P, Rosen R: Current status of platelet NO synthases. Thromb Res 1997;87:51-55.
6. Mendes Ribeiro AC, Brunini TMC, Ellory JC, Mann GE: Abnormalities of nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc Res 2001;49:697-712.
7. +L in human monocytes. Am J Physiol 2004;571:177-181.
8. Welt LG, Sachs JR, Macmanus TJ: An ion transport defect from uremic patients. Trans Assoc Am Physiol 1964;77:169-181.
9. Flam BR , Hartmann PJ, Harrell-Booth M, Solomonson LP, Eichler DC: Caveolar localization of arginine regeneration enzymes, argininosuccinate synthase, and lyase, with endothelial nitric oxide synthase. Nitric Oxide 2001;5:187-197.
10. McDonald KK, Zharikov S, Block ER, Kilberg MS: A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the 'arginine paradox'. J Biol Chem 1997;272:31213-31216.
11. Closs EI, Simon A, Vékony N, Rotmann A: Plasma membrane transporters for L-arginine. J Nutr 2004;134:2752S-2759S.
12. Devés R, Boyd AR: Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev 1998;78:487-544.
13. Mann GE, Yudilevich DL, Sobrevia L: Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 2003;83:182-252.
14. +L as the high-affinity transporter for L-arginine in human platelets: up-regulation of L-arginine influx in uraemia. Pflügers Arch Eur J Physiol 1999;438:573-575.
15. Cotton JR, Woodward T, Carter NW, Knochel JP: Resting skeletal muscle membrane potential as index uremic toxicity. J Clin Invest 1979;63:501-506.
16. Edmondson RP, Hilton PJ, Jones NF, Patrick J, Thomas RD: Leukocyte sodium transport in uraemia. Clin Sci Mol Med 1975;49:213-216.
17. Fervenza FC, Harvey CM, Hendry BM, Ellory: Increased lysine transport capacity in erythrocytes from patients with chronic renal failure. Clin Sci 1989;76:419-422.
18. Fraser CL, Sarnacki AP, Arieff AI: Abnormal sodium transport in synaptosomes from brain of uraemic rats. J Clin Invest 1985;75:2014-2023.
19. Vanholder R, Glorieux G, Lameire N: New insights in uremic toxicity. Contrib Nephrol. Basel, Karger, 2005, vol 149, pp 315-324.
20. Vanholder R, Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clarck W, Cohen G, Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kid Int 2003;63:1934-1943.
21. Tepel M, Theilmeier G, Bachmann J, Barenbrock M, Spieker C, Ganten D, Rahn KH, Zidek W: Increased cytosolic sodium and reduced Na,K-ATPase activity in transgenic rats. Hypertension 1994;23(1 suppl):198-202.
22. da Silva CD, Brunini TM, Reis PF, Moss MB, Santos SF, Roberts NB, Ellory JC, Mann GE, Mendes-Ribeiro AC: Effects of nutritional status on the L-arginine-nitric oxide pathway in platelets from haemodialysis patients. Kid Int 2005;68:2173-2179.
23. +L-like: a tertiary active transport mechanism for renal reabsorption of cysteine and dibasic amino acids. J Biol Chem 1996;271:17761-17770.
24. Déves R, Angelo S: Changes in membrane and surface potential explain the opposite effects of low ionic strength on the two lysine transporters of human erythrocytes. J Biol Chem 1996;271:32034-32039.
25. Flores C, Rojas S, Aguayo C, Parodi J, Mann G, Pearson JD, Casanello P, Sobrevia L: Rapid stimulation of L-arginine transport by D-glucose involves p42/44(mapk) and nitric oxide in human umbilical vein endothelium. Circ Res 2003;92:64-72.
26. 2+ in human platelets. FEBS Letters 1999;461:43-46.
27. Visigalli R, Bussolati O, Sala R, Barilli A, Rotoli BM, Alessandro P, Alamanni F, Gazzola GC, Dall'Asta: The stimulation of arginine transport by TNFα in human endothelial cells depends on NF-κB activation. Biochim Biophys Acta 2004;1664:45-52.
28. Zharikov SI: Role of membrane potential in hypoxic inhibition of L-arginine uptake by lung endothelial cells. Am J Physiol 1997;272:L78-L84.
29. +) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. J.Physiol 1996;490:775-781.
30. Corona-de-la-Pena N, Uribe-Carvajal S, Barrientos-Rios R, Matias-Aguilar L, Montiel-Manzano G, Majluf-Cruz A: Polyamines inhibit both platelet aggregation and glycoprotein IIb/IIIa activation. J Cardiovasc Pharmacol 2005;46:216-221.
31. Brunini TMC, Yaqoob M, Novaes Malagris LE, Ellory JC, Mann GE, Mendes Ribeiro: Increased nitric oxide synthesis in uraemic platelets is dependent on L-arginine transport via system y(+)L. Pflügers Arch 2003;445:547-550.
32. +L/4F2hc is a heteromultimeric complex. FASEB J 1998;12:1319-1329.
33. +L) in human erythrocytes that recognizes lysine and leucine with high affinity. FASEB J 1992;454:491-501.
34. +L in human umbilical vein endothelium. Exp Physiol 2003;88:699-710.
35. +. Am J Physiol 2002;282:C134-C143.
36. Radomki MW, Palmer RM, Moncada S: An L-arginine/ nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-5197.
37. Leoncini G, Bruzzese D, Signorello MG: The L-arginine/NO pathway in the early phases of platelet stimulation by collagen. Bioch Pharm 2005;29:289-296.
38. Schoner W: Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem 2002;269:2440-2448.